KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Inventory (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Inventory for 17 consecutive years, with $6.5 billion as the latest value for Q4 2025.

  • Quarterly Inventory rose 4.75% to $6.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 billion through Dec 2025, up 4.75% year-over-year, with the annual reading at $6.5 billion for FY2025, 4.75% up from the prior year.
  • Inventory hit $6.5 billion in Q4 2025 for Abbott Laboratories, down from $6.7 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $7.0 billion in Q2 2025 to a low of $5.2 billion in Q4 2021.
  • Historically, Inventory has averaged $6.2 billion across 5 years, with a median of $6.5 billion in 2023.
  • Biggest five-year swings in Inventory: rose 19.7% in 2022 and later fell 5.72% in 2024.
  • Year by year, Inventory stood at $5.2 billion in 2021, then grew by 19.7% to $6.2 billion in 2022, then grew by 6.43% to $6.6 billion in 2023, then dropped by 5.72% to $6.2 billion in 2024, then rose by 4.75% to $6.5 billion in 2025.
  • Business Quant data shows Inventory for ABT at $6.5 billion in Q4 2025, $6.7 billion in Q3 2025, and $7.0 billion in Q2 2025.